Skip to main content
The Egyptian Journal of Bronchology
Download PDF

The impact of adjuvant atorvastatin therapy on community-acquired pneumonia outcome: a prospective study of clinical and inflammatory responses in relation to mortality reduction

Egyptian Journal of Bronchology volume 13, pages 249–257 (2019)Cite this article

Abstract

Introduction

In treatment of pneumonia, new drugs besides antibiotics are investigated; especially statins with their anti-inflammatory, immunomodulatory, and antioxidant effects.

Objective

The aim was to determine whether or not adjuvant atorvastatin could improve 30-day mortality, and clinical and inflammatory outcomes of community-acquired pneumonia (CAP).

Patients and methods

This is a prospective study, in which 47 CAP patients were randomized into: statin naive, n=23 (received antibiotics according to guidelines) and statin users, n=24 (received antibiotics according to guidelines +atorvastatin 40mg daily for 30 days). Total leukocytic count and C-reactive protein (CRP) were measured, pneumonia severity index was estimated on the first day and on the seventh day, and length of hospital stay and mortality were also recorded.

Results

Statin users showed statistically significant reduction of CRP (P=0.049) and significantly shorter hospital stay (P<0.001). No statistically significant difference on comparing both groups as regard the reduction magnitude of total leukocytic count (P=0.406), pneumonia severity index (P=0.325), and mortality (P=0.489).

Conclusion

Incorporating atorvastatin therapy with antibiotics compared to antibiotics alone in the treatment of CAP showed significantly lower CRP levels, shorter hospital stay, but no impact on mortality reduction.

References

  1. World Health Organization. 2017. The top 10 causes of death. Available at:http://www.who.int/mediacentre/factsheets/fs310/en. [Accessed on 2017 Mar 19].

  2. World Health Organization. 2012. WHO statistical profile. Egypt:WHO. Available at:http://www.who.int/gho/countries/egy.pdf. [Accessed on 2016 June 1].

  3. Meijvis S, van de Garde E, rijkers G, Bos W. Treatment with antiinflammatory drugs in community acquired pneumonia. J Intern Med 2012; 272:25–35.

    Article  CAS  Google Scholar 

  4. Terblanche M, Almog Y, Rosenson R, Smith T, Hackam D. Statins and sepsis:multiple modifi cations at multiple levels. Lancet Infect Dis 2007; 7:358–368.

    Article  CAS  Google Scholar 

  5. Fine M, Auble T, Yealy D, Hanusa B, Eeissfeld L, Singer D, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. NEJM 1997; 336:243–250.

    Article  CAS  Google Scholar 

  6. Kruger P, Bailey M, Bellomo R, Cooper D, Harward M, Higgins A, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187:743–750.

    Article  CAS  Google Scholar 

  7. Patel J, Snaith C, Thickett D, Linhartova L, Melody T, Hawkey P, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012; 16:R231.

  8. Viasus D, Garcia-Vidal C, Simonetti A, Dorca J, Llopis F, Mestre M, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia:a randomised, double-blind, placebo-controlled trial. BMJ Open 2015; 5:e006251–e006251.

    Article  Google Scholar 

  9. Bruyere R, Vigneron C, Prin S, Pechinot A, Quenot J, Aho S, et al. Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia:an observational study. Crit Care 2014; 18:R83.

  10. Papazian L, Roch A, Charles P, Penot-Ragon C, Perrin G, Roulier P, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia. JAMA 2013; 310:1692–1700.

    Article  CAS  Google Scholar 

  11. Craig T, Duffy M, Shyamsundar M, McDowell C, O’Kane C, Elborn J, et al. A Randomized clinical trial of hydroxymethylglutaryl– coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011; 183:620–626.

    Article  CAS  Google Scholar 

  12. Shyamsundar M, McKeown S, O’Kane C, Craig T, Brown V, Thickett D, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009; 179:1107–1114.

    Article  CAS  Google Scholar 

  13. Novak V, Eisinger M, Frenkel A, Terblanche M, Adhikari N, Douvdevani A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections:a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009; 35:1255–1260.

    Article  Google Scholar 

  14. Steiner S, Speidl W, Pleiner J, Seidinger D, Zorn G, Kaun C, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111:1841–1846.

    Article  CAS  Google Scholar 

  15. FDA. Drug safety communication:new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2017. Available at:https://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. [Accessed on 2017 Jan 25].

  16. Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003; 92:152–160.

    Article  CAS  Google Scholar 

  17. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582–587.

    Article  CAS  Google Scholar 

  18. Shankar-Hari M, Donnelly A, Pinto R, Salih Z, McKenzie C, Terblanche M, et al. The influence of statin exposure on inflammatory markers in patients with early bacterial infection:pilot prospective cohort study. BMC Anesthesiol 2014; 14:R106.

  19. Mortensen E, Nakashima B, Cornell J, Copeland L, Pugh M, Anzueto A, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55:1466–1473.

    Article  CAS  Google Scholar 

  20. Havers F, Bramley A, Finelli L, Reed C, Self W, Trabue C, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired Pneumonia. Clin Infect Dis 2016; 62:1471–1478.

    Article  Google Scholar 

  21. Majumdar S, McAlister F, Eurich D, Padwal R, Marrie T. Statins and outcomes in patients admitted to hospital with community acquired pneumonia:population based prospective cohort study. BMJ 2006; 333:1–5.

    Article  Google Scholar 

  22. Cheng H, Tang T, He Q, Huang L, Lin X, Chen M, et al. Beneficial effects of statins on outcomes in pneumonia:a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18:2294–2305.

    PubMed  Google Scholar 

  23. Nielsen A, Nielsen R, Riis A, Johnsen S, Sørensen H, Thomsen R. The impact of statin use on pneumonia risk and outcome:a combined population-based case-control and cohort study. Crit Care 2012; 16: R122.

  24. Liao J, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89–118.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Diseases, Ain Shams University, 54 Abdel Rahman Elrafaey Street, El Hegaz Square, Heliopolis, Cairo, 11786, Egypt

    Yasser M. Mohamed, Ashraf M. Madkour & Rehab M. Mohammed MD, PhD

  2. Department of Chest Diseases, General Organization of Institutes and Teaching Hospitals, Cairo, Egypt

    Mohamed G. El-Shiekh

Authors
  1. Yasser M. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashraf M. Madkour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rehab M. Mohammed MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed G. El-Shiekh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rehab M. Mohammed MD, PhD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohamed, Y.M., Madkour, A.M., Mohammed, R.M. et al. The impact of adjuvant atorvastatin therapy on community-acquired pneumonia outcome: a prospective study of clinical and inflammatory responses in relation to mortality reduction. Egypt J Bronchol 13, 249–257 (2019). https://doi.org/10.4103/ejb.ejb_50_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_50_17

Keywords